Tirzepatide

What Tirzepatide Is

Tirzepatide is a synthetic 39-amino-acid peptide engineered by Eli Lilly (development code LY3298176) that functions as a dual agonist of the GIP and GLP-1 incretin receptors. It is distinct from most compounds profiled on this platform because it is a fully FDA-approved finished drug, not a research-use compound. It reached market under two brand names: Mounjaro, approved in May 2022 for glycemic control in adults with type 2 diabetes, and Zepbound, approved in November 2023 for chronic weight management. In December 2024 the FDA extended the Zepbound label to moderate-to-severe obstructive sleep apnea in adults with obesity, making tirzepatide the first drug approved for that condition. Structurally it is built on a modified GIP backbone, with an aminoisobutyric acid substitution that resists DPP-4 degradation and a C20 fatty-diacid chain that binds serum albumin, giving a half-life of roughly five days and enabling once-weekly subcutaneous dosing in trials.

Mechanism of Action

Tirzepatide activates two incretin hormone pathways with a single molecule. Via the GLP-1 receptor it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on central appetite circuits to reduce food intake. Via the GIP receptor it further amplifies insulin response and, in published pharmacology, is proposed to influence energy expenditure and lipid metabolism. Pharmacology studies describe it as binding the GIP receptor with affinity similar to native GIP while binding the GLP-1 receptor somewhat more weakly than native GLP-1. Researchers hypothesize that this combined dual-agonism accounts for metabolic effects larger than those seen with selective GLP-1 receptor agonists, though the precise contribution of the GIP component remains an active area of investigation.

What Published Research Has Examined

Tirzepatide is among the most heavily studied peptides in the medical literature, with development anchored by two large phase 3 programs. The SURPASS trials assessed glycemic control in type 2 diabetes, including the pivotal head-to-head SURPASS-2 study against injectable semaglutide 1 mg (NEJM, 2021). The SURMOUNT trials assessed chronic weight management, led by SURMOUNT-1 in adults with obesity or overweight without diabetes (NEJM, 2022). SURMOUNT-OSA (NEJM, 2024) evaluated adults with moderate-to-severe obstructive sleep apnea and obesity, across cohorts using and not using positive airway pressure therapy. Additional published trials and analyses have examined cardiovascular risk factors, systolic blood pressure, and hepatic outcomes in metabolic dysfunction-associated steatohepatitis, alongside ongoing investigation of oral formulations and comparisons with other incretin agents.

Key Findings

In SURPASS-2, all three tirzepatide doses produced greater reductions in A1c and body weight than semaglutide 1 mg, with the 15 mg dose achieving roughly twice the weight loss of semaglutide. In SURMOUNT-1, mean body-weight reduction reached about 20.9% at the 15 mg dose on the treatment-regimen estimand (and up to ~22.5% on the efficacy estimand) over 72 weeks, versus about 2 to 3% with placebo, with a large majority of 15 mg participants losing at least 20% of body weight. In SURMOUNT-OSA, tirzepatide reduced the apnea-hypopnea index substantially versus placebo over 52 weeks, alongside improvements in body weight, hypoxic burden, hsCRP, and blood pressure.

Regulatory Status

Tirzepatide is FDA Approved. It is important to distinguish it from the compounding-bulks conversation: tirzepatide is a finished, approved drug, not a Category 2 substance under review, and it is not among the seven peptides on the FDA Pharmacy Compounding Advisory Committee's July 23-24, 2026 docket (BPC-157, TB-500, KPV, MOTS-c, emideltide, epitalon, and semax). Like semaglutide and bremelanotide, tirzepatide sits entirely outside the 503A bulks-list process because it already has full FDA approval for specific indications.

Safety Considerations & Related Compounds

Because tirzepatide is approved, its adverse-event profile is characterized in prescribing information and across thousands of trial participants. The most common events reported in SURPASS and SURMOUNT were gastrointestinal, chiefly nausea, diarrhea, vomiting, and constipation, generally mild to moderate and concentrated during dose escalation. Labeling and trial reports also note decreased appetite, possible gallbladder events, pancreatitis, and hypoglycemia when combined with insulin or sulfonylureas, plus a class boxed warning for rodent thyroid C-cell tumors whose human relevance is unestablished. Closely related compounds include the single-agonist GLP-1 drug semaglutide, the triple GIP/GLP-1/glucagon agonist retatrutide, the glucagon/GLP-1 agonist survodutide, the amylin analog cagrilintide, and the earlier GLP-1 agonist liraglutide. This platform reports the published literature and does not offer medical advice.

Key published studies

Regulatory status

Current status: FDA Approved. FDA Approved. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.

Related compounds

Read our full guide on whether peptides are safe.